Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

NCT06848920 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT06848920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06848920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2025
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

differentiated thyroid carcinoma (dtc), neoadjuvant therapy